ÀÖÓ㣨Leyu£©ÌåÓý¹ÙÍø

Although the pharmaceutical industry was vulnerable to ransomware attacks and intellectual property theft before the pandemic, drug manufacturers have moved higher on the list of potential cyber-crime targets. Headline-grabbing COVID vaccines and treatments, as well as lucrative biologics and perennial brand-name drugs, have called attention to pharma companies� financial reserves and valuable trade secrets.

There is no doubt that the pharmaceutical industry has entered a new era of mutual concern.  We believe that it is critical to increase cross-institutional collaboration not only on treatments and vaccines for COVID-19 and future global health crises, but also on ensuring that third-party suppliers and partners maximize their cybersecurity postures. In other words, toppling silos will only make the industry stronger. 

In this spirit of cross-institutional collaboration, ÀÖÓ㣨Leyu£©ÌåÓý¹ÙÍø assembled a team of CISOs and subject matter experts from Johnson & Johnson (J&J), Pfizer, Cardinal Health, McKesson, Abbott, and Eli Lilly to create a proprietary security framework for the pharmaceutical supply chain.  Spearheaded by ÀÖÓ㣨Leyu£©ÌåÓý¹ÙÍø cybersecurity leaders, together with industry membership organization Health-ISAC and J&J, the framework centers on a CISO guide to working with the business to address top security risks, including insights from pharma CISOs on the top six security threats and how to address them (â€�Securing the modern pharmaceutical supply chainâ€�).

The hope is that this framework will be a work in progress and that other members of the Health-ISAC community—and the pharmaceutical industry at large—will weigh in as the pharmaceutical ecosystem evolves.